Sequencing Immunotherapy and Hypofractionated Radiotherapy in Frail Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
Current Oncology · 22.04.2026 · 33 (5) · 239
DOI: 10.3390/curroncol33050239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 22.04.2026. Verfasst von Beatrice Bettazzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences M. Serio, University of Florence, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immunotherapy, Radiation Dose Hypofractionation, Head and Neck Neoplasms. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Hypofractionated radiotherapy and immunotherapy (IT) are possible treatment options for HNSCC patients unsuitable for standard curative treatment, yet no high-level evidence supports their combined use. We aim to report on the clinical outcome of a single-center cohort of HNSCC patients treated with a hypofractionated radiotherapy (hypoRT) regimen in combination with IT alone or chemo-immunotherapy (CT-IT). (2)
Methods
We enrolled a cohort of elderly and frail HNSCC patients unsuitable for standard curative treatment, deemed candidates to undergo hypoRT in a sequential strategy (time interval < 6 months), followed or preceded by IT alone (hypoRT_IT) or CT-IT. We selected our sample using the Geriatric 8 (G8) score and the Charlson Comorbidity Index (CCI). (3)
Results
At a median follow-up of 11 months (IQR 5–20), the median locoregional control (LRC) was 12 months (95% CI 7.0–17.1) with a 1-year progression-free survival rate of 63%. For the hypoRT-IT group, the median overall survival was 12 months (95% CI 0–24). No grade (G) 4–5 in-field acute side effects were observed, while one case of G3 oral mucositis and two cases of G3 radiation dermatitis were reported. (4)
Conclusions
A sequential combination of checkpoint inhibitors and hypoRT may provide clinical benefit with acceptable toxicity in frail and elderly patients with advanced HNSCC unfit for standard therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental and Clinical Biomedical Sciences M. Serio, University of Florence, 50134 Florence, Italy.
- Department of Radiation Oncology, Careggi University Hospital, 50134 Florence, Italy.
- Istituto Fiorentino di Cura e Assistenza (IFCA), 50139 Florence, Italy.
- Histopathology and Molecular Diagnostics, Careggi University Hospital, 50134 Florence, Italy.
ORCID-Profile: Viola Salvestrini, Marco Banini, Pierluigi Bonomo
Zitieren
APA
Bettazzi, B., Salvestrini, V., Banini, M., Ruggieri, O., Palomba, A., Galli, I. C., Livi, L., Bonomo, P., & Becherini, C. (2026). Sequencing Immunotherapy and Hypofractionated Radiotherapy in Frail Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Current Oncology, 33(5), 239. https://doi.org/10.3390/curroncol33050239
Vancouver
Bettazzi B, Salvestrini V, Banini M, Ruggieri O, Palomba A, Galli IC, et al. Sequencing Immunotherapy and Hypofractionated Radiotherapy in Frail Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Current Oncology. 2026;33(5):239. doi:10.3390/curroncol33050239
BibTeX
@article{Bettazzi2026,
author = {Bettazzi, Beatrice and Salvestrini, Viola and Banini, Marco and Ruggieri, Olga and Palomba, Annarita and Galli, Ilaria Camilla and Livi, Lorenzo and Bonomo, Pierluigi and Becherini, Carlotta},
title = {Sequencing Immunotherapy and Hypofractionated Radiotherapy in Frail Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {5},
pages = {239},
doi = {10.3390/curroncol33050239}
}
EUVIMED